在阿特佐利祖马布/贝瓦西祖马布治疗进展后,晚期HCC的二线治疗模式和结果
Meng Wu1, Claudia A M Fulgenzi2, Antonio D'Alessio2,3
1Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.
JHEP reports : innovation in hepatology
|January 29, 2025
概括
在治疗晚期肝细胞癌 (HCC) 后继续主动治疗阿特佐利祖马布/贝瓦齐祖马布 (A/B) 显著改善了存活率. 基于免疫检查点抑制剂 (IO) 的疗法显示,与氨酸激酶抑制剂 (TKI) 相比,进展后的生存时间更长.
科学领域:
- 肝细胞癌研究 肝细胞癌研究
- 瘤学治疗策略 癌症治疗策略
- 癌症护理中的现实世界证据
背景情况:
- 阿特佐利祖马布/贝瓦西祖马布 (A/B) 是治疗晚期肝细胞癌 (HCC) 的标准一线治疗方法.
- 在HCC中A/B进展后,最佳的二线治疗仍未确定.
- 由于缺乏1级数据,需要对现实世界结果进行调查.
研究的目的:
- 评估先进的HCC患者在一线A/B治疗中进展的现实世界治疗模式和结果.
- 确定与改善后进展生存率 (PPS) 相关的因素.
- 为了比较不同二线全身疗法的疗效.
主要方法:
- 406名先进的HCC患者进行了多中心,国际,回顾性研究,这些患者在一线A/B治疗中进展.
- 主要结局:进展后生存期 (PPS),定义为从进展到死亡的时间.
- 多变量考克斯回归分析以确定PPS的预测因子.
主要成果:
- 整个队列的PPS中位数为6.0个月.
- 继续积极治疗的患者 (n=222) 的mPPS显著长 (9.7个月) 与最佳支持性治疗 (BST) (n=184,2.6个月) 相比.
- 基于免疫检查点抑制剂 (IO) 的疗程 (14.9个月) 显示,mPPS比氨酸激酶抑制剂 (TKI) (8.4个月) 长.
结论:
- 在A/B进展后继续积极治疗独立地与晚期HCC的更好的存活率有关.
- 基于IO的治疗可能会提供超越进展的持续益处.
- 进一步调查TKI和IO方案的最佳序列是有必要的.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K